IKT · Insider Trading
Inhibikase Therapeutics, Inc. Common Stock
Every open-market purchase and sale reported by IKT officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-10-21 | Scott M. Wasserman | Director | A | +310,000 deriv. | — |
| 2026-07-31 | Dennis N Berman | Director | M | +21,854 | +$27.54K |
| 2026-07-31 | Rajeev M. Shah | 10%+ Owner | J | −72,120,000 | — |
| 2026-02-24 | Christopher Cabell | President & Head of R&D | D | −338,282 | — |
| 2026-02-24 | Amit Munshi | Director | D | −19,089 | — |
| 2026-02-24 | Vincent Aurentz | Director | D | −255,299 | — |
| 2026-01-07 | Christopher Cabell | President & Head of R&D | A | +900,117 deriv. | — |
| 2026-01-07 | David McIntyre | Chief Financial Officer | A | +986,319 deriv. | — |
| 2026-01-07 | Mark T Iwicki | Chief Executive Officer | A | +4,982,706 deriv. | — |
| 2025-11-24 | Sands Capital Alternatives, LLC | 10%+ Owner | Buy | +6,206,895 | +$9.00M |
| 2025-08-28 | Amit Munshi | Director | A | +57,265 | — |
| 2025-07-02 | David Canner | Director | A | +108,176 deriv. | — |
| 2025-07-02 | Dennis N Berman | Director | A | +108,176 deriv. | — |
| 2025-07-02 | Arvind Kush | Director | A | +108,176 deriv. | — |
| 2025-07-02 | Vincent Aurentz | Director | A | +108,176 deriv. | — |
| 2025-07-02 | Amit Munshi | Director | A | +108,176 deriv. | — |
| 2025-07-02 | Roberto Bellini | Director | A | +108,176 deriv. | — |
| 2025-07-02 | Christopher Cabell | President & Head of R&D | A | +1,100,705 deriv. | — |
| 2025-07-02 | Vincent Aurentz | Director | A | +134,427 deriv. | — |
| 2025-07-02 | Mark T Iwicki | Chief Executive Officer | A | +602,346 deriv. | — |
| 2025-04-16 | David McIntyre | Chief Financial Officer | A | +1,775,539 deriv. | — |
| 2025-02-25 | Mark T Iwicki | Chief Executive Officer | A | +602,346 deriv. | — |
| 2025-02-25 | Christopher Cabell | President & Head of R&D | A | +1,100,705 deriv. | — |
| 2025-02-25 | Vincent Aurentz | Director | A | +134,427 deriv. | — |
| 2025-02-19 | Arvind Kush | Director | A | +173,185 deriv. | — |
| 2025-02-19 | Roy Lester Freeman | Director | A | +22,640 deriv. | — |
| 2025-02-19 | Mark T Iwicki | Chief Executive Officer | A | +6,168,148 deriv. | — |
| 2025-02-19 | Dennis N Berman | Director | A | +68,968 deriv. | — |
| 2025-02-19 | David Canner | Director | A | +139,225 deriv. | — |
| 2025-02-19 | Dennis N Berman | Director | A | +39,620 deriv. | — |
| 2025-02-19 | Roberto Bellini | Director | A | +190,165 deriv. | — |
| 2025-02-19 | Amit Munshi | Director | A | +173,185 deriv. | — |
| 2025-01-22 | Garth Lees-Rolfe | Chief Financial Officer | MIXED | — | — |
| 2025-01-22 | Milton H. Werner | President and CEO | MIXED | — | — |
| 2025-01-22 | Roy Lester Freeman | Director | MIXED | — | — |
| 2025-01-22 | Dennis N Berman | Director | MIXED | — | — |
| 2025-01-07 | Roy Lester Freeman | Director | A | +833,290 deriv. | — |
| 2025-01-07 | Dennis N Berman | Director | A | +833,290 deriv. | — |
| 2025-01-07 | Garth Lees-Rolfe | Chief Financial Officer | A | +1,139,097 deriv. | — |
| 2025-01-07 | Milton H. Werner | President and CEO | A | +11,582,471 deriv. | — |
| 2024-10-23 | David Canner | Director | A | +60,000 deriv. | — |
| 2024-10-23 | Amit Munshi | Director | Buy | +365,000 | +$500.05K |
| 2024-10-23 | Arvind Kush | Director | Buy | +145,000 | +$198.65K |
| 2024-10-23 | Roberto Bellini | Director | Buy | +1,460,000 | +$2.00M |
| 2024-07-18 | Dennis N Berman | Director | A | +30,000 deriv. | — |
| 2024-07-18 | Roy Lester Freeman | Director | A | +30,000 deriv. | — |
| 2024-07-18 | Gisele Dion | Director | A | +30,000 deriv. | — |
| 2024-07-18 | Paul C Grint | Director | A | +30,000 deriv. | — |
| 2024-04-03 | Milton H. Werner | President and CEO | A | +45,000 deriv. | — |
| 2024-04-02 | Garth Lees-Rolfe | Chief Financial Officer | A | +90,000 deriv. | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| Sands Capital Alternatives, LLC | 10%+ Owner | 13,018,965 | $19.79M |
| Rajeev M. Shah | 10%+ Owner | 6,970,000 | $10.59M |
| Roberto Bellini | Director | 1,460,000 | $2.22M |
| Milton H. Werner | President and CEO | 893,171 | $1.36M |
| Christopher Cabell | President & Head of R&D | 676,564 | $1.03M |
| Vincent Aurentz | Director | 510,596 | $776.11K |
| Amit Munshi | Director | 403,176 | $612.83K |
| Arvind Kush | Director | 145,000 | $220.40K |
| Dennis N Berman | Director | 21,854 | $33.22K |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the IKT quote page; the site-wide leaderboard is on the insider transactions hub.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.